Literature DB >> 2586101

The nude mouse as a model for the study of human pancreatic cancer.

F M Marincola1, B J Drucker, D Y Siao, K L Hough, W D Holder.   

Abstract

The purpose of this study was to characterize an in vivo model of human pancreatic cancer suitable for chemotherapy and immunotherapy studies. In this study we report a 2-year experience in growing the MIA PaCa-2 (CRL 1420) human pancreatic cancer cell line in 92 adult (8 weeks old) and 256 young (3-6 weeks old) nude mice. Ten million tumor cells were transplanted into orthotopic (duodenal lobe of the pancreas) and/or heterotopic positions (hepatic and subcutaneous) and data on operative mortality, effect of total body irradiation (TBI), tumor growth kinetics, and survival are presented comparing the two age groups. Operative mortality was due to anesthetic intolerance which was higher in the young mouse population (13.4% versus 5.7%). Adult mice withstood TBI (500 rad) without mortality but young mice were highly sensitive to radiation damage and their maximum tolerated dose (LD50) was 425-450 rad. Subcutaneous tumors grew significantly more often in young compared to adult animals (97.9% versus 69%) and this finding was not affected by TBI (96.9% versus 75%), though tumors did appear more quickly after TBI. An average of 14.7 +/- 2.8 days was required for the subcutaneous tumors to become macroscopically apparent in the adult population compared with 3.1 +/- 0.8 days in the young mice. The largest subcutaneous tumor diameter 28 days following tumor implant averaged 9.3 +/- 0.6 mm in the young animals and 5.5 +/- 1.7 mm in the adult population (P less than 0.01). Treatment of young mice with human recombinant interleukin-2 (IL-2) (10,000 Units twice a day for 28 days) produced a 27% decrease in tumor growth. This effect was abolished by prior irradiation of the young mice with 375 rad TBI. Pancreatic tumor growth also occurred more consistently in young than in adult animals (91.2% versus 64.3%) and irradiation did not affect pancreatic tumor take in either group. Occasionally intrapancreatic tumor growth was associated with liver metastases in animals that were killed after 28 days (17.8% in young and 22.2% in adult animals). However, when more than 45 days elapsed before sacrificing the animals, the incidence of hepatic metastases increased to 57.1%. This was slightly less than the incidence of hepatic lesions found after direct injection of cancer cells into the liver by portal vein injection (71.4%). Direct extension of tumor into surrounding tissues was common with frequent involvement of the duodenum (83.7%), kidneys (30.6%), and other intraabdominal organs (43.9%). Survival was significantly longer in adult compared to young mice.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Year:  1989        PMID: 2586101     DOI: 10.1016/0022-4804(89)90130-3

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  13 in total

1.  Characterization of the invasive and metastatic phenotype in human renal cell carcinoma.

Authors:  I Saiki; S Naito; J Yoneda; I Azuma; J E Price; I J Fidler
Journal:  Clin Exp Metastasis       Date:  1991 Nov-Dec       Impact factor: 5.150

Review 2.  Technical considerations for studying cancer metastasis in vivo.

Authors:  D R Welch
Journal:  Clin Exp Metastasis       Date:  1997-05       Impact factor: 5.150

3.  Chronologically-specific metastatic targeting of human pancreatic tumors in orthotopic models.

Authors:  M Bouvet; M Yang; S Nardin; X Wang; P Jiang; E Baranov; A R Moossa; R M Hoffman
Journal:  Clin Exp Metastasis       Date:  2000       Impact factor: 5.150

4.  Matrix metalloproteinase inhibition improves survival in an orthotopic model of human pancreatic cancer.

Authors:  E E Zervox; M G Franz; K F Salhab; A E Shafii; J Menendez; W R Gower; A S Rosemurgy
Journal:  J Gastrointest Surg       Date:  2000 Nov-Dec       Impact factor: 3.452

5.  Different radiogenic effects on microcirculation in healthy pancreas and in pancreatic carcinoma of the rat.

Authors:  Eduard Ryschich; Jan Schmidt; Thorsten Loeffler; Michel Eble; Martha Maria Gebhard; Wolfgang Harms; Ernst Klar
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

6.  Treatment of pancreatic carcinoma by adenoviral mediated gene transfer of vasostatin in mice.

Authors:  L Li; Y-Z Yuan; J Lu; L Xia; Y Zhu; Y-P Zhang; M-M Qiao
Journal:  Gut       Date:  2005-11-15       Impact factor: 23.059

7.  A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens.

Authors:  X Fu; F Guadagni; R M Hoffman
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-15       Impact factor: 11.205

Review 8.  Orthotopic implantation of human colon carcinomas into nude mice provides a valuable model for the biology and therapy of metastasis.

Authors:  I J Fidler
Journal:  Cancer Metastasis Rev       Date:  1991-10       Impact factor: 9.264

9.  Development of an orthotopic human pancreatic cancer xenograft model using ultrasound guided injection of cells.

Authors:  Amanda Shanks Huynh; Dominique F Abrahams; Monica S Torres; Margaret K Baldwin; Robert J Gillies; David L Morse
Journal:  PLoS One       Date:  2011-05-27       Impact factor: 3.240

10.  MUC4 mucin expression in human pancreatic tumours is affected by organ environment: the possible role of TGFbeta2.

Authors:  A Choudhury; N Moniaux; A B Ulrich; B M Schmied; J Standop; P M Pour; S J Gendler; M A Hollingsworth; J-P Aubert; S K Batra
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.